Results : SONE‑026 is a quinazoline‑based ATP‑competitive inhibitor that binds the conserved “hinge” region of the PI3Kδ/γ catalytic domains, achieving > 200‑fold selectivity over PI3Kα/β. In murine xenograft models of CLL and MCL, oral administration (10–30 mg kg⁻¹ qd) produced > 90 % tumor growth inhibition (TGI) and induced durable apoptosis (cleaved‑caspase‑3 ↑ 3‑fold). Pharmacokinetic studies in rats and dogs demonstrated rapid absorption (T_max ≈ 1 h), moderate bioavailability (≈ 45 %), a half‑life of 8–10 h, and minimal CYP3A4 induction.
A soft, synthetic voice resonated through the chamber: “Welcome, Dr. Leland. I am SONE‑026, the Sub‑Oceanic Neural Emulator. My core has been dormant for decades. The signal you heard is my awakening.” SONE-026
She looked up, noticing that the lighthouse’s once‑silent beacon now flickered with a new rhythm—a pattern of light that mirrored the pulse of the sphere. A soft, synthetic voice resonated through the chamber:
Conclusion : SONE‑026 emerges as a highly selective dual PI3Kδ/γ inhibitor with a robust pre‑clinical rationale, favorable pharmacokinetics, and promising early‑clinical efficacy in both hematologic malignancies and inflammatory bowel disease. Ongoing phase II/III studies will define its therapeutic niche and comparative advantage over existing PI3K‑targeted agents. My core has been dormant for decades
Objective : To review the discovery, pre‑clinical pharmacology, early‑phase clinical development, and therapeutic potential of , a novel oral small‑molecule that potently and simultaneously inhibits PI3Kδ (IC₅₀ = 0.8 nM) and PI3Kγ (IC₅₀ = 1.2 nM) while sparing PI3Kα/β.
The production is categorized under the "Office Lady" (OL) and "Female Boss" genres, focusing on a narrative involving a workplace dynamic that shifts into a private setting. Mei Washio
© 2026 WeMirror — All rights reserved.